GL1X · GenesisL1 explorer

MolNFT v1 · #144049 · protein

Mouse immunoglobulin G 2C Fc fragment with complex-type glycan

6BHQ · Igh protein: “Mouse immunoglobulin G 2C Fc fragment with complex-type glycan”. X-ray diffraction, 5 ligands (NAG, MAN, BMA), 2 pockets (best druggability 0.43). MolNFT v1 #144049 on GenesisL1: 3D structure, binding sites and pockets…

PDB
6BHQ
Type
protein
Length
407 residues
Chains
2
Method
x-ray diffraction
Collection
MolNFT v1 / PDB
Contract
0xDE3723766Bc32dcACD03C17BaA400A7B36837Eba
Owner
0x3396CDB397284571d12822B4ae1189a8E22AAAAA
Molecule
Igh protein
UniProt
Q58E56
Ligands
NAG, MAN, BMA, GAL, FUL
Pockets
2 · best druggability 0.43

Structure

x-ray diffraction · 2 distinct chains · 11% helix, 48% strand (DSSP).

ChainMoleculeTypeResiduesSecondary structureUniProt
AIgh proteinprotein20810% helix, 50% strandQ58E56
BIgh proteinprotein19911% helix, 46% strandQ58E56

Ligands and binding sites

  • NAG · 2-acetamido-2-deoxy-beta-D-glucopyranose · sugar · 6 copies · chains A, B
  • MAN · alpha-D-mannopyranose · sugar · 4 copies · chains A, B
  • BMA · beta-D-mannopyranose · sugar · 2 copies · chains A, B
  • GAL · beta-D-galactopyranose · sugar · 2 copies · chains A, B
  • FUL · beta-L-fucopyranose · sugar · 2 copies · chains A, B
  • GOL · Glycerol · additive · chains A

Binding sites are the residues within 4.5 Å of a ligand's heavy atoms.

Pockets

2 pockets found on a 1 Å grid, 0 with a druggability of 0.5 or more.

PocketVolume (ų)DruggabilityBuriednessLining residuesInside
1630.430.8222empty
2500.390.8213empty

Interfaces

1 interface between chains.

  • A–B · 1134 Ų buried · 15 hydrogen bonds · protein-protein

Modifications

Observed in the structure: 4 disulfide, 1 glycan (disulfide, N-glycosylation).

Compared structures

  • 6BHQ · Mouse Immunoglobulin G 2c Fc fragment with complex-type glycan · the same entry in another collection · chain A against A, TM-score 1.00

Analyse

GL1X is a live explorer of the GenesisL1 blockchain. Turn on JavaScript for search, charts and interactive views.